Systemic vasculitides are a heterogeneous group of diseases characterized by inflammation of vessels, which can result in their obstruction and/or aneurysm formation. The evidence of the inflammation of blood vessel walls in at least one occasion during the course is a shared defining feature of all categories of vasculitis. Their classification varies according to etiology, pathogenesis, type of vessel affected, type of inflammation, and favored organ distribution. Almost all primary vasculitides can target the heart; even if cardiac manifestations are rarely predominant, they can be life threatening and, therefore, require specific diagnostic and therapeutic strategies. Although cardiac involvement occurs in less than 10% of all patients affected by systemic vasculitides, certain entities, such as eosinophilic granulomatosis with polyangiitis (EGPA) and Takayasu’s arteritis (TAK) can cause heart complications in up to 60% of patients. After briefly reviewing the definitions, classification, and pathogenic mechanisms of vasculitides, we describe the cardiac manifestations that can occur in each vasculitis and their corresponding therapies.

Cardiac Involvement in Systemic Vasculitis / Sebastiani, Marco; Manfredi, Andreina Teresa; Ferri, Clodoveo. - 14:(2017), pp. 335-376. [10.1016/B978-0-12-803997-7.00014-4]

Cardiac Involvement in Systemic Vasculitis

SEBASTIANI, Marco;MANFREDI, Andreina Teresa;FERRI, Clodoveo
2017

Abstract

Systemic vasculitides are a heterogeneous group of diseases characterized by inflammation of vessels, which can result in their obstruction and/or aneurysm formation. The evidence of the inflammation of blood vessel walls in at least one occasion during the course is a shared defining feature of all categories of vasculitis. Their classification varies according to etiology, pathogenesis, type of vessel affected, type of inflammation, and favored organ distribution. Almost all primary vasculitides can target the heart; even if cardiac manifestations are rarely predominant, they can be life threatening and, therefore, require specific diagnostic and therapeutic strategies. Although cardiac involvement occurs in less than 10% of all patients affected by systemic vasculitides, certain entities, such as eosinophilic granulomatosis with polyangiitis (EGPA) and Takayasu’s arteritis (TAK) can cause heart complications in up to 60% of patients. After briefly reviewing the definitions, classification, and pathogenic mechanisms of vasculitides, we describe the cardiac manifestations that can occur in each vasculitis and their corresponding therapies.
2017
The Heart in Systemic Autoimmune Diseases. Second Edition
Atzeni F., Sarzi-Puttini P
9780128039977
Elsevier
REGNO UNITO DI GRAN BRETAGNA
Cardiac Involvement in Systemic Vasculitis / Sebastiani, Marco; Manfredi, Andreina Teresa; Ferri, Clodoveo. - 14:(2017), pp. 335-376. [10.1016/B978-0-12-803997-7.00014-4]
Sebastiani, Marco; Manfredi, Andreina Teresa; Ferri, Clodoveo
File in questo prodotto:
File Dimensione Formato  
Heart in vasculitis.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 3.96 MB
Formato Adobe PDF
3.96 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1141341
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact